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Variants of the melanocortin-1 receptor (MC1R) gene have been linked to sun-sensitive skin types and hair colour, and may
independently play a role in susceptibility to cutaneous melanoma. To assess the role of MC1R variants in uveal melanoma, we have
analysed a cohort of 350 patients for the changes within the major region of the gene displaying sequence variation. Eight variants
were detected – V60L, D84E, V92M, R151C, I155T, R160W, R163Q and D294H – 63% of these patients being hetero- or
homozygous for at least one variant. Standard melanoma risk factor data were available on 119 of the patients. MC1R variants were
significantly associated with hair colour (P¼0.03) but not skin or eye colour. The frequency of the variants detected in the 350
patients was comparable with those in the general population, and comparison of the cumulative tumour distribution by age at
diagnosis in carriers and noncarriers provided no evidence that MC1R variants confer an increased risk of uveal melanoma. We
interpret the data as indicating that MC1R variants do not appear to be major determinants of susceptibility to uveal melanoma.
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Uveal melanoma although rare is the most common primary
intraocular malignancy in adults with an incidence of six per
million per year (Parkin et al, 1992). Compared to cutaneous
melanoma, little is known about the aetiology of the disease.
Recognised risk factors for cutaneous melanoma include pale skin
and fair hair, number of naevi, atypical naevi, tendency to freckle
and sensitivity to sunlight (Bliss et al, 1995). While both cutaneous
and uveal melanomas develop from melanocytes originating in the
neural crest and also share several histological characteristics,
there are distinctive differences between the two types of tumour
in terms of cytogenetic anomalies and familial inheritance.
Unlike cutaneous melanoma, the genetic predisposition to uveal
melanoma has not been studied extensively. While segregation of
uveal melanoma and cutaneous melanoma and an association with
atypical melanoma have been reported (Bataille et al, 1993; van
Hees et al, 1998), most of the uveal melanomas appear to be
sporadic (Lynch et al, 1968; Canning and Hungerford, 1988; Singh
et al, 1996). Several studies have suggested that atypical naevi, light
eye colour and exposure to ultraviolet radiation each represent
independent risk factors for uveal melanoma, just as they do for
cutaneous melanoma (Rootman and Gallagher, 1984; Dolin and
Johnson, 1994; Bataille et al, 1995; Regan et al, 1999). The inference
from these data is that genetic susceptibility to uveal melanoma is
likely to be mediated through sensitivity to ultraviolet radiation.
Melanin pigmentation plays an important role in affording
protection against the deleterious effects of ultraviolet radiation. In
humans, a-melanocyte-stimulating hormone (a-MSH) and other
pro-opiomelanocortin peptides modulate melanin pigment forma-
tion via the melanocortin-1 receptor (MC1R) on melanocytes
(Sturm et al, 2001). Two melanin pigments have been identified in
humans: black eumelanin and red phaeomelanin. The relative
proportions of these pigments are controlled by a-MSH via MC1R.
Eumelanin is protective, but phaeomelanin may contribute to
carcinogenesis through production of free radicals (Ranadive et al,
1986; Sturm, 1998). Several point mutations in MC1R affecting
function have been identified, for example, V60L, R151C, R160W,
D294H, some of which have been reported to be over-represented
in individuals with fair hair and skin (Valverde et al, 1995;
Flanagan et al, 2000; Box et al, 2001a,b). In addition to acting as
determinates of pigmentation, some variants may confer an
increased risk of cutaneous melanoma (Valverde et al, 1996;
Healy et al, 1999; Palmer et al, 2000). MC1R genotype has been
shown to have a persisting effect on risk of cutaneous melanoma
and nonmelanoma skin cancer even after adjusting for hair and
skin colour, which supports the notion that MC1R may directly
modulate melanocyte growth and differentiation (Valverde et al,
1996).
We have assessed the risk of uveal melanoma associated with
germline MC1R variants through sequence analysis of 350 patients
and a series of 133 population controls. We have also evaluated the
role of these variants as determinants of skin type, hair and eye
colour, and cutaneous naevus count in 119 of the patients.
PATIENTS AND METHODS
Patients
A total of 350 unrelated patients with uveal melanoma attending
the Liverpool Ocular Oncology Centre (LOOC) between 1994 and
1997, either for treatment of a newly diagnosed tumour (n¼300)
or for review after previous treatment (n¼50), were studied. In all, Revised 29 August 2003; accepted 11 September 2003
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s183 of the patients were male (52%). The average age at diagnosis
of uveal melanoma was 58 years (s.d. 13, range 22–89). The
diagnosis of uveal melanoma was based on ophthalmoscopy and
ultrasonography performed by an experienced examiner (BD) and,
in patients treated by enucleation or local resection, was confirmed
by histology. There was no selection of patients. The only
exclusion criterion was being nonwhite.
Standard risk factors for cutaneous melanoma, propensity to
sunburn, pigmentation (skin colour, hair colour at 15 years, eye
colour) and number of cutaneous naevi were collected by interview
and clinical examination in 119 consecutive patients aged 18–60
years. Hair colour was classified into: red, auburn, blond/fair, light
brown, medium brown, dark brown and black. A three-point scale
was used for eye colour, using the categories ‘blue’, ‘green/grey’
and ‘hazel/brown’. Skin type was classified using an extension of
Fitzpatrick’s scheme (1988) as follows: type I, individuals who
always burn and never tan; type II, always burn then tan slightly
(mild tanning); type III, sometimes burn and always tan (moderate
tanning); type IV, burn minimally and tan easily; type V, rarely
burn and tan deeply; type VI, intense tanning with no burning.
Blood samples from 133 healthy spouses of colorectal cancer
cases served as controls – 53 males and 80 females, mean age 56
years (s.d. 9, range 30–89). None of the controls had a personal
history of malignancy. All were Caucasian and their ancestry was
from the British Isles.
Blood samples and clinical data were obtained with informed
consent and Local Ethical Review Board approval in accordance
with the tenets of the Declaration of Helsinki.
Molecular analyses
DNA was extracted from EDTA venous blood samples using a
standard sucrose lysis protocol. Detection of sequence variation in
MC1R nucleotides 107–492 was undertaken by sequencing. Two
sets of overlapping primers M1F 50-AGCCCGGTGCCTG-
GAGGTGT-30 and M1R 50-TGGTAGCGCAGTGCGTAGAA-30 and
M2F 50-GGGAGCAAC(GA)TGCTGGAGAC-30 and M2R 50-
ACCGGGCGCTGCCTCTTGTG-30 were used and sequences deter-
mined using the ABI Ready Reaction Dye Terminator Cycle
Sequencing Kit and ABI377 or ABI3100 semiautomated sequen-
cers. Sequence analysis was undertaken using Sequence Navigator
Software (PE Applied Biosystems, Foster City, CA, USA), and
nucleotide changes identified in MC1R were referenced to the
published sequence (Genbank accession number NM_002386). The
D294H variant was detected using a polymerase chain reaction
restriction fragment length polymorphism. A 330bp fragment of
MC1R was amplified by PCR using the primers: M3F, 50-
ACCATCCTGCTGGGCATTTT-30 and 50-ACGGGGACCAGG-
GAGGTAAG-30. The PCR product was digested with TaqIi n
accordance with the manufacturers’ recommendations (New
England Biolabs Inc., Beverly, MA, USA). The G-allele (D294) is
cleaved generating 150 and 180bp fragments cleavage whereas the
A-allele (294H) is refractory to cleavage. Cleavage products were
visualised on 2% agarose gels and digest products confirmed by
sequencing. Two researchers confirmed sequence and genotyping
analyses.
Statistical analyses
All statistical analyses were performed using the statistical software
program STATA Version 7 (Stata Corporation 702 University
Drive East, College Station, TX 77840, USA. http://www.stata.com).
The distribution of categorical variables was compared by either w
2
or Fisher’s exact test. ANOVA or t-test was used to test differences
in the distribution of normally distributed continuous variables.
Naevi counts were log transformed to normalise their distribution.
Carrier and noncarrier cumulative tumour distributions by age at
diagnosis were compared using log-rank test. The relationship
between MC1R genotype and risk of uveal melanoma was assessed
by means of the odds ratio (OR) with 95% confidence limits
calculated by unconditional logistic regression adjusting for age
and sex. A test for trend (Ptrend) in increasing the risk of uveal
melanoma by having more than one putative high-risk allele of
MC1R was also evaluated. Pooled estimates of the OR for this and
previously published studies were obtained by calculating a
weighted-average of the logarithm of ORs (Breslow and Day,
1987). Studies were weighted according to the inverse of the
variance of the log of the OR. A P-value of 0.05 was considered
statistically significant.
RESULTS
Eight variants were detected – V60L, D84E, V92M, R151C, I155T,
R160W, R163Q, D294H – among the patients and controls studied
(Table 1). The frequencies of combinations of MC1R variants did
not differ from expected observed allele frequencies (data not
shown). Hence, the MC1R variants can be considered as
independent variants and consequently were analysed as such.
The frequencies of the MC1R variants that have been reported in
190 UK population controls – D84E (3.5%), V92M (17.3%) and
D294H (6.8%) (Ichii-Jones et al, 1998) – are not statically different
from that observed in the cases and controls in our study. In
Table 1 Relationship between MC1R variants and risk of uveal melanoma in this study
Cases Controls OR
a 95% CI
a
Number of MC1R variants
0 129/350 (36.9%) 50/133 (37.6%) 1.0 —
1 154/350 (44.0%) 55/133 (41.4%) 1.09 (1.09) 0.69–1.70 (0.70–1.72)
2+ 67/350 (19.1%) 28/133 (21.0%) 0.93 (0.96) 0.54–1.61 (0.55–1.68)
Any variant 221/350 (63.1%) 83/133 (62.4%) 1.03 (1.05) 0.68–1.56 (0.69–1.60)
Frequency of MC1R variant
V60L 77/350 (22.0%) 36/133 (27.3%) 0.73 (0.76) 0.44–1.15 (0.48–1.22)
D84E 9/350 (2.6%) 4/133 (3.0%) 0.67 (0.60) 0.22–2.05 (0.19–1.89)
V92M 62/350 (17.7%) 21/133 (15.8%) 1.15 (1.09) 0.67–1.97 (0.62–1.89)
R151C 50/350 (14.2%) 19/133 (14.4%) 1.00 (0.98) 0.57–1.77 (0.55–1.76)
I155T 3/350 (0.9%) 1/133 (0.8%) 1.14 (0.75) 0.12–11.07 (0.07–7.52)
R160W 48/350 (13.7%) 15/133 (11.4%) 1.16 (1.23) 0.63–2.13 (0.66–2.29)
R163Q 22/350 (6.3%) 12/133 (9.1%) 0.68 (0.78) 0.32–1.41 (0.37–1.68)
D294H 19/350 (5.4%) 4/133 (3.0%) 1.85 (1.88) 0.62–5.55 (0.61–5.78)
aOR and 95% CI values adjusted for age and sex are given in parentheses.
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D294H variants are not statistically different from the frequencies
previously documented in the 738 individuals of Northern
European ancestry reported by Vajdic et al (2003) (23.2, 2.8,
20.6, 15.6 and 6.0%, respectively).
Information on hair colour, eye colour and skin type had been
recorded in 119 of the patients. There was a strong relationship
between skin and fair hair and eye colour (Po0.05). The
relationship between these three phenotypes and MC1R variation
is detailed in Table 2. No significant association was seen between
possession of one or more MC1R variants and eye colour
(P¼0.46). Similarly, no significant relationship was seen between
skin type and possession of a MC1R variant (P¼0.29) or naevus
count (P¼0.45). There was, however, an association between
MC1R status and hair colour with an over-representation of
variants in individuals with light or red hair (P¼0.03).
The frequency of each of the MC1R variants in the 350 patients
was not statistically different from that observed in the controls. Of
the 350 patients studied, 129 (36.9%) had no MC1R variants, 154
(44.0%) had one MC1R variant and 67 (19.1%) possessed two or
more variants.
The mean ages at diagnosis in noncarriers and carriers of one
and two or more of MC1R variants in our study were not
significantly different – 57.9, s.d. 14; 58.0, s.d. 13 and 58.0, s.d. 12,
respectively; P¼0.99. Similarly, the cumulative distributions of
age at diagnosis in carriers of one and two or more variants, and
noncarriers were not significantly different.
Two research groups have previously reported on the relation-
ship between MC1R variants and risk of uveal melanoma –
Metzelaar-Blok et al (2001) based on analysis of 162 patients
and Vajdic et al (2003) based on analysis of 62 patients. In
both studies, there was no difference in the frequency of variants in
cases compared to controls. Table 3 summarises the results from
these two studies. Also shown are pooled estimates of the risk of
uveal melanoma based on all studies for individual variants and
one, two or more and any MC1R variant. In pooling studies, there
was no evidence of heterogeneity. No statistically significant
associations between risk and MC1R status were detected in this
analysis.
DISCUSSION
We performed this study to determine whether germline MC1R
variants confer an increased risk of uveal melanoma. Our
investigation was prompted by the observation that patients with
uveal melanomas have a greater number of cutaneous naevi than
that of the general population, and that numbers of cutaneous
naevi, as well as skin and hair colour, are a function of MC1R
genotype (Bataille et al, 1995).
The frequency of MC1R variants detected in patients in our
study was not significantly different from the frequencies in the
general population, and were very similar to estimates obtained in
unselected North-European populations. Furthermore, we found
that the age at diagnosis of uveal melanoma in carriers of MC1R
variants was not significantly different from noncarriers. These
findings imply that MC1R variants are unlikely to confer an
increased risk of uveal melanoma. The main strengths of our study
are the large number of patients in our sample and correlation of
MC1R variants with age at diagnosis, a factor that has not
previously been investigated.
In our study, we detected eight MC1R variants: V60L, D84E
V92M, R151C, I155T, R160H, R163Q and D294H. Linkage
disequilibrium has been reported to exist between certain variants
(Palmer et al, 2000). In our study this was nondetectable; however,
our study was not empowered to explore this. Previous studies
have demonstrated a relationship between MC1R variants and hair
and skin type, notably a strong association between the R151C,
R160Q and R294H variants, with fair skin and red hair (Valverde
et al, 1995; Palmer et al, 2000; Bastiaens et al, 2001). Collectively,
the MC1R variants we detected were over-represented in the
patients with light skin and red or fair hair, in keeping with these
previous observations. The relationship was, however, less
pronounced than in some previous studies, largely because of
the small number of patients with red or auburn hair and type I
skin type in our study.
Most, but not all, previous studies have shown that MC1R
variants are associated with an increased risk of both cutaneous
melanoma (Valverde et al, 1996; Palmer et al, 2000) and
nonmelanoma skin cancers (Box et al, 2001a,b). There is some
Table 2 Numbers of homo- and heterozygotes for MC1R alleles in patients according to skin type, and hair and eye colour
MC1R variant
a
Phenotype V60L D84E V92M R151C I155T R160W R163Q D294H Combined
Skin type
I( n¼13) 1 1 3 2 0 2 3 2 10
II (n¼38) 6 0 7 7 0 11 2 2 26
III (n¼29) 7 0 6 3 0 5 2 1 20
IV (n¼25) 3 1 8 3 0 3 1 1 16
V( n¼12) 3 1 2 1 0 0 0 0 6
VI (n¼2) 0 0 0 0 0 0 0 0 0
Hair colour
Red (n¼2) 0 1 0 0 0 0 0 1 2
Auburn (n¼7) 2 0 0 1 0 3 1 2 6
Blond (n¼16) 2 0 3 8 0 3 2 2 15
Light brown (n¼26) 3 0 7 1 0 4 1 1 14
Medium brown (n¼20) 4 0 7 2 0 4 0 0 14
Dark brown (n¼35) 6 0 7 3 0 4 3 0 20
Black (n¼13) 2 2 2 1 0 2 0 0 7
Eye colour
Blue (n¼68) 10 0 17 11 0 8 5 3 44
Green-grey (n¼12) 2 0 2 0 0 4 0 1 7
Hazel-brown (n¼39) 9 3 7 5 0 9 3 2 28
aCompound heterozygotes appear in more than one column under the analysis of individual alleles, but only once in the combined column. Thus, the ‘‘combined’’ column does
not necessarily represent the sum of values for the individual alleles.
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type. This suggests that certain MC1R variants can exert an effect
on melanoma tumorigenesis in a dual manner, both as a
determinant of fair skin and as a component in an independent
additional pathway (Palmer et al, 2000; Van der Velden et al,
2001).
Our data support the findings of Metzelaar-Blok et al (2001) and
the recent study reported by Vajdic et al (2003), who found no
relationship between variation in MC1R and risk of uveal
melanoma. Moreover, pooling data from all three studies provide
no evidence that variants confer an increased risk of uveal
melanoma. We cannot, however, exclude the possibility that
variants confer very small increases in risk of B1.1-fold.
In our study, the majority of patients had blue eyes in keeping
with the finding of Regan et al (1999), who reported that uveal
melanoma is more common in individuals with light irises,
suggesting that increased sensitivity to sunlight from prolonged
ultraviolet exposure represents a risk factor. Hence, our findings
do not necessarily contradict the observation that ultraviolet
radiation and pigmentation probably represent risk factors for
uveal melanoma. However, in contrast to cutaneous melanoma,
most of the patients with uveal melanomas in our study and other
reports (Metzelaar-Blok et al, 2001) do not have type I or type II
skin.
Although of a common embryological origin, there are several
biological differences between uveal, conjunctival and cutaneous
melanocytes (Sarna, 1992). Firstly, there is no evidence that
ultraviolet light initiates melanogenesis in uveal melanomas (Sahm
et al, 2001). Secondly, it is unclear whether uveal melanocytes
continue to synthesise melanin in adulthood (Hu et al, 1995).
Lastly, whereas epidermal melanocytes synthesise melanosomes
and export these to keratinocytes, melanosomes within uveal
melanocytes remain relatively inactive (Boissy, 1988). These
differences may explain at least in part why incidence rates of
uveal melanoma do not show such geographical differences to
those seen in cutaneous melanoma. Moreover, differences in the
relative importance of aetiological factors between the two tumour
types are reflected at the molecular level – activating mutations of
BRAF are almost universal in cutaneous melanomas but not in
uveal tumours (Davies et al, 2002; Cohen et al, 2003; Edmunds et al,
2003).
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